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TO THE EDITOR
Environmental and genetic factors have
been found to influence manifestation
and severity of psoriasis. The most
prominent environmental factor possi-
bly leading to psoriasis is smoking and
the related nicotine exposure, as was
again discussed in this year’s publica-
tion with data from an Italian case–-
control study (Naldi et al., 2005).
Among the genetic factors that have
been found to influence psoriasis are
also key detoxifying enzymes metabo-
lizing toxins from tobacco smoke.
Variant alleles of CYP1A1, which code
for enzymes with higher activity, were
found to protect against psoriasis in a
study carried out by our group (Richter-
Hintz et al., 2003).
If smoking and the related nicotine
exposure is a risk factor for psoriasis,
then the association between psoriasis
and the non-variant genotype of
CYP1A1, which codes for enzymes
with lower activity should be stronger
in smokers than in non-smokers. This
was investigated with the data from our
study (Richter-Hintz et al., 2003) where
the influence of smoking was not
evaluated so far. Interactions between
smoking and CYP1A1 polymorphisms
have been found for a number of
other diseases including arteriosclerosis
(Wang et al., 2002a) and adverse birth
outcomes (Wang et al., 2002b), but
have not been investigated for psoriasis
before.
Our study on genetic factors of
psoriasis was approved by the local
ethical committee. The 321 Caucasian
psoriasis patients and 235 unrelated
controls gave written consent before
being recruited. Standardized inter-
views were performed, and begin,
end, amount, and frequency of smoking
and alcohol consumption were asked
for. Subjects were assigned smoker, ex-
smoker, and non-smoker accordingly.
CYP1A1 polymorphisms (alleles
*1A, *2A, and *2C) were determined
by restriction fragment length poly-
morphism as described (Richter-Hintz
et al., 2003). Allele *1A is the non-
variant sequence, *2A has a 3801 T4G
exchange, and *2C has a 2455A4G
exchange.
Logistic regression was used for
analysis. The CYP1A1 genotype with
no variant alleles was coded as 1 and
the others as zero. Gender and age
were included as covariates. The ana-
lysis was done for never-smokers, ex-
smokers and smokers separately.
Of the controls 56% were never
smokers, 24% were ex-smokers, and
20% were smokers, and in the psoriasis
cases, 32% never smoked, 25%
gave up smoking, and 43% were
smokers. This difference in smoking
behavior was highly significant (w2-test,
Po0.0001). Thirteen percent of the
controls and 12% of the cases stated
that they drank alcohol every day (no
significant difference).
Table 1 demonstrates that the non-
variant genotype of CYP1A1, which
codes for enzymes with lower activity
was significantly associated with psor-
iasis in smokers, less in ex-smokers but
not in non-smokers. In controls, the
frequency of the non-variant geno-
type does not vary across the strata
defined by smoking behavior, whereas
in psoriasis cases, this genotype was
more often in smokers than in never
smokers.
The associations found strengthen
the view that smoking might cause the
manifestation of psoriasis. A modifica-
tion of the effect of smoking by CYP1A1
polymorphisms was already investi-
gated in cancer, arteriosclerosis, and
adverse birth outcomes. In all these
cases, however, the smoking-related
risks were more frequent in the variant
genotypes, where enzyme activity is
increased. This is different in psoriasis.
The mechanism by which smoking affe-
cts psoriasis might be different from the
mechanism in cancer, arteriosclerosis,
and adverse birth outcomes. The risk
association identified here indirectly
points to non-metabolized xenobiotics
as etiological agents of psoriasis. Nico-
tine might be a candidate.
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Table 1. Frequency of the non-variant CYP1A1 genotype in psoriasis cases and controls stratified by smoking
behavior
Psoriasis cases1 (%) (n) Controls1 (%) (n) Adjusted2 odds ratio (95% confidence interval) P-value
Never smokers 81.8 (88) 75.0 (116) 1.64 (0.80–3.38) 0.1766
Ex-smokers 88.2 (68) 76.5 (51) 2.88 (1.03–8.03) 0.0431
Smokers 91.7 (120) 76.2 (42) 3.56 (1.35–9.37) 0.0103
All 87.7 (276) 75.6 (209) 2.48 (1.52–4.03) 0.0003
1Only cases and controls with complete information about smoking behavior were included in the calculation.
2Adjusted for age and gender.
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